Lately, Ark Biosciences, an innovative R&D enterprise of antiviral drugs announced that its D-round financing has been completed. Shanghai FTZ Fund and its Sci-tec Innovation Fund have continued the investment as the current share holder, fully supporting Ark Biosciences' future R&D and commercialization.

Dr. Wu Zheng, founder and CEO of Ark Biosciences, stated, "Ark Biosciences has been deeply involved in the fields of children and respiratory diseases, and our core product has completed Phase III clinical trials. Ark Biosciences will continue to move forward, developing more innovative drugs with clinical value for patients in China and around the world."